Senators Fear Viral Spread Of Gilead Pricing Strategy
This article was originally published in Scrip
Executive Summary
While it was Gilead Sciences Inc.'s hepatitis C virus (HCV) treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) that was at the center of a bipartisan congressional investigation into how the company priced those drugs, the concern by the lawmakers who initiated the probe was what would happen if the company's approach is adopted by other firms selling blockbuster specialty medicines for Alzheimer's, cancer, diabetes and HIV.